Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. HUD designation covers devices that treat rare, orphan diseases or conditions. The HUD designation is the first step …